Sisram Medical Ltd. (HK:1696) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sisram Medical Ltd has announced the approval of its botulinum toxin type A product, DAXXIFY®, for cosmetic use in Mainland China, marking its first injectable product launch in the region. The Company obtained the sublicense rights in December 2022 for the commercialization of DAXXIFY® in Mainland China, Hong Kong, and Macau from Shanghai Fosun Pharmaceutical Industrial, with the original licensor being U.S.-based Revance Therapeutics, Inc. Sisram Medical expects DAXXIFY® to significantly bolster its product portfolio and strengthen its position in the global aesthetic market.
For further insights into HK:1696 stock, check out TipRanks’ Stock Analysis page.